Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 12 de 12
Filter
1.
Clin. transl. oncol. (Print) ; 25(7): 2169-2182, jul. 2023.
Article in English | IBECS | ID: ibc-222386

ABSTRACT

Purpose The present consensus statement was developed by the GINECOR working group on behalf of the Spanish Society of Radiation Oncology (SEOR). This document provides an up-to-date review of the technical aspects in radiation treatment of vulvar cancer. Methods A two-round modified Delphi study was conducted to reach consensus on the appropriateness of technical aspects of external beam radiotherapy and brachytherapy. Three clinical scenarios were proposed: adjuvant treatment of vulvar cancer, radiation treatment of locally advanced vulvar carcinoma and locoregional recurrences. After the first round, an extensive analysis of current medical literature from peer-reviewed journal was performed to define evidence-based treatment options. In the second round, participants were asked to indicate their level of agreement with the preliminary recommendations according to the GRADE (Grade of Recommendation, Assessment, Development, and Evaluation) criteria, as follows: strongly agree; agree; neither agree nor disagree; disagree and strongly disagree. Results The main recommendations on external beam radiotherapy and brachytherapy, both in adjuvant setting and local advanced disease are summarized. Recommendations include treatment technique, treatment volume, and doses in target and organs at-risk. Taking into consideration the different clinical scenarios of recurrent disease, the radiation treatment should be individualized. Conclusions In the absence of robust clinical data, these recommendations may help to select the optimal radiotherapy approach for this relatively rare cancer (AU)


Subject(s)
Humans , Female , Vulvar Neoplasms/radiotherapy , Radiotherapy, Adjuvant , Chemoradiotherapy , Brachytherapy , Societies, Medical , Consensus , Spain
3.
Clin Transl Oncol ; 25(7): 2153-2168, 2023 Jul.
Article in English | MEDLINE | ID: mdl-36961727

ABSTRACT

PURPOSE: The present consensus statement was developed by the GINECOR working group on behalf of the Spanish Society of Radiation Oncology (SEOR). Given the lack of prospective data on the management of vulvar carcinoma, this document provides an up-to-date review of radiotherapy treatment in vulvar cancer and a series of consensus-based recommendations from a group of experts. METHODS: A two-round, online modified Delphi study was conducted to reach consensus treatment recommendations in three clinical settings: 1) adjuvant treatment, 2) locally-advanced vulvar cancer (LAVC), and 3) recurrent disease. After the first round, we comprehensively reviewed the available medical literature from peer-reviewed journals to assess and define the evidence-based treatment options. In the second round, participants were asked to indicate their level of agreement with the preliminary recommendations according to the GRADE (Grade of Recommendation, Assessment, Development, and Evaluation) criteria, as follows: strongly agree; agree; neither agree nor disagree; disagree; strongly disagree. RESULTS: The main recommendations were as follows: 1) following surgical resection, adjuvant radiotherapy is recommended with the presence of adverse risk factors (primarily positive margins and lymph node involvement); 2) radiotherapy (with or without chemotherapy) should be considered in LAVC; and 3) in recurrent disease, radiotherapy should be individualised on a case-by-case basis. A high level of agreement over 80% was reached. CONCLUSIONS: In the absence of robust clinical data, these final recommendations may help to select the optimal radiotherapy approach for this relatively rare cancer.


Subject(s)
Radiation Oncology , Vulvar Neoplasms , Female , Humans , Vulvar Neoplasms/radiotherapy , Radiotherapy, Adjuvant , Lymph Nodes/pathology , Consensus
4.
Clin Transl Oncol ; 25(7): 2169-2182, 2023 Jul.
Article in English | MEDLINE | ID: mdl-36961728

ABSTRACT

PURPOSE: The present consensus statement was developed by the GINECOR working group on behalf of the Spanish Society of Radiation Oncology (SEOR). This document provides an up-to-date review of the technical aspects in radiation treatment of vulvar cancer. METHODS: A two-round modified Delphi study was conducted to reach consensus on the appropriateness of technical aspects of external beam radiotherapy and brachytherapy. Three clinical scenarios were proposed: adjuvant treatment of vulvar cancer, radiation treatment of locally advanced vulvar carcinoma and locoregional recurrences. After the first round, an extensive analysis of current medical literature from peer-reviewed journal was performed to define evidence-based treatment options. In the second round, participants were asked to indicate their level of agreement with the preliminary recommendations according to the GRADE (Grade of Recommendation, Assessment, Development, and Evaluation) criteria, as follows: strongly agree; agree; neither agree nor disagree; disagree and strongly disagree. RESULTS: The main recommendations on external beam radiotherapy and brachytherapy, both in adjuvant setting and local advanced disease are summarized. Recommendations include treatment technique, treatment volume, and doses in target and organs at-risk. Taking into consideration the different clinical scenarios of recurrent disease, the radiation treatment should be individualized. CONCLUSIONS: In the absence of robust clinical data, these recommendations may help to select the optimal radiotherapy approach for this relatively rare cancer.


Subject(s)
Brachytherapy , Carcinoma , Radiation Oncology , Vulvar Neoplasms , Female , Humans , Vulvar Neoplasms/radiotherapy , Neoplasm Recurrence, Local/radiotherapy
5.
World J Clin Oncol ; 12(9): 767-786, 2021 Sep 24.
Article in English | MEDLINE | ID: mdl-34631441

ABSTRACT

Optimal management after recurrence or progression of high-grade gliomas is still undefined and remains a challenge for neuro-oncology multidisciplinary teams. Improved radiation therapy techniques, new imaging methods, published experience, and a better radiobiological knowledge of brain tissue have positioned re-irradiation (re-RT) as an option for many of these patients. Decisions must be individualized, taking into account the pattern of relapse, previous treatment, and functional status, as well as the patient's preferences and expected quality of life. Many questions remain unanswered with respect to re-RT: Who is the most appropriate candidate, which dose and fractionation are most effective, how to define the target volume, which imaging technique is best for planning, and what is the optimal timing? This review will focus on describing the most relevant studies that include re-RT as salvage therapy, with the aim of simplifying decision-making and designing the best available therapeutic strategy.

6.
World J Clin Oncol ; 10(2): 38-51, 2019 Feb 24.
Article in English | MEDLINE | ID: mdl-30815370

ABSTRACT

Technological advances in radiotherapy have led to the introduction of techniques such as stereotactic body radiation therapy (SBRT), allowing the administration of ablative doses. The hypothesis that oligometastatic disease may be cured through local eradication therapies has led to the increasing use of SBRT in patients with this type of disease. At the same time, scientific advances are being made to allow the confirmation of clinically suspected oligometastatic status at molecular level. There is growing interest in identifying patients with oligometastatic prostate cancer (PCa) who may benefit from curative intent metastasis-directed therapy, including SBRT. The aim is to complement, replace or delay the introduction of hormone therapy or other systemic therapies. The present review aims to compile the evidence from the main ongoing studies and results on SBRT in relation to oligometastatic PCa; examine aspects where gaps in knowledge or a lack of consensus persist (e.g., optimum schemes, response assessment, identification and diagnosis of oligometastatic patients); and document the lack of first-level evidence supporting the use of such techniques.

7.
World J Clin Oncol ; 8(4): 366-370, 2017 Aug 10.
Article in English | MEDLINE | ID: mdl-28848704

ABSTRACT

Pulmonary artery intimal sarcoma (PAIS) is a rare tumor with a very poor prognosis. Clinical and radiological findings usually mimic thromboembolic disease, leading to diagnostic delays. The treatment of choice is surgery, and adjuvant chemotherapy and radiotherapy have limited results. We report the case of a 48-year-old male patient, initially suspected with pulmonary thromboembolism. The angio-CT revealed a filling defect in the pulmonary artery trunk. The patient underwent surgery, resulting in with complete resection of the mass with a diagnosis of PAIS. The tumor progressed rapidly in the lung, requiring surgery of multiple lung metastases. The patient was treated with stereotactic body radiation therapy (SBRT) on two occasions for new pulmonary lesions. In the last followup (4 years after initial diagnosis), the patient was disease-free. In conclusion, SBRT proved to be an alternative treatment to metastasectomy, allowing palliative chemotherapy to be delayed or omitted, which may result in improved quality of life.

8.
Cir. Esp. (Ed. impr.) ; 94(8): 460-466, oct. 2016. tab, graf
Article in Spanish | IBECS | ID: ibc-156225

ABSTRACT

INTRODUCCIÓN: La radioterapia preoperatoria de curso corto con cirugía inmediata, mejora el control local del cáncer rectal. Las respuestas que consigue son de menor magnitud que las descritas con radioquimioterapia. Datos preliminares asocian esta menor respuesta al corto periodo hasta la cirugía. El objetivo de este estudio es analizar la respuesta obtenida con el esquema preoperatorio de curso corto y su correlación con el tiempo hasta la cirugía, analizando especialmente a los pacientes con fascia mesorrectal afectada. MÉTODOS: Se analiza retrospectivamente a 155 pacientes tratados con radioterapia preoperatoria (5×5Gy). Se cuantificó la respuesta tumoral en términos de tasas de respuesta completa patológica, reducción del estadio, grado de regresión tumoral y estado del margen de resección circunferencial. RESULTADOS: El intervalo medio radioterapia-cirugía fue de 23 días. Se alcanzaron respuestas completas patológicas en el 2,2% y reducción del estadio en el 28%. No se detectaron diferencias entre estas tasas y el intervalo hasta la cirugía. Ochenta y ocho pacientes tenían resonancia de estadificación (31 con fascia mesorrectal comprometida). La media de tiempo hasta la intervención en pacientes con fascia comprometida y cirugía R0 fue de 27 días y si R1 de 16 días (p = 0,016). El punto de corte de 20 días alcanzó la mayor probabilidad de lograr un margen circunferencial negativo entre los pacientes con fascia mesorrectal comprometida, aunque sin alcanzar significación estadística: RR 3,036, IC del 95%=0,691-13,328, p = 0,06. CONCLUSIONES: Tras la radioterapia preoperatoria de curso corto, un intervalo > 20 días potencia la probabilidad de lograr un margen de resección libre en pacientes con fascia mesorrectal comprometida


INTRODUCTION: Preoperative short-course radiotherapy with immediate surgery improves local control in patients with rectal cancer. Tumor responses are smaller than those described with radiochemotherapy. Preliminary data associate this lower response to the short period until surgery. The aim of this study is to analyze the response to preoperative short-course radiotherapy and its correlation with the interval to surgery especially analyzing patients with mesorectal fascia involvement. METHODS: A total of 155 patients with locally advanced rectal cancer treated with preoperative radiotherapy (5×5Gy) were retrospectively analyzed. Tumor response in terms of rates of complete pathological response, downstaging, tumor regression grading and status of the circumferential resection margin were quantified. RESULTS: The mean interval from radiotherapy to surgery was 23 days. The rate of complete pathological response was 2.2% and 28% experienced downstaging (stage decreased). No differences between these rates and interval to surgery were detected. Eighty-eight patients had magnetic resonance imaging for staging (in 31 patients the mesorectal fascia was involved).The mean time to surgery in patients with involvement of the fascia and R0 surgery was 27 days and 16 days if R1 (P = .016). The cutoff of 20 days reached the highest probability of achieving a free circumferential resection margin between patients with mesorectal fascia involvement, with no statistically significant differences: RR 3.036 95% CI = (0.691-13.328),P = .06. CONCLUSIONS: After preoperative short-course radiotherapy, an interval>20 days enhances the likelihood of achieving a free circumferential resection margin in patients with mesorectal fascia involvement


Subject(s)
Humans , Male , Female , Adult , Middle Aged , Aged , Aged, 80 and over , Rectal Neoplasms/pathology , Rectal Neoplasms/radiotherapy , Rectal Neoplasms/surgery , Positron-Emission Tomography/instrumentation , Positron-Emission Tomography/methods , Comorbidity , Radiotherapy/methods , Radiotherapy , Retrospective Studies , 28599
9.
Cir Esp ; 94(8): 460-6, 2016 Oct.
Article in English, Spanish | MEDLINE | ID: mdl-27461232

ABSTRACT

INTRODUCTION: Preoperative short-course radiotherapy with immediate surgery improves local control in patients with rectal cancer. Tumor responses are smaller than those described with radiochemotherapy. Preliminary data associate this lower response to the short period until surgery. The aim of this study is to analyze the response to preoperative short-course radiotherapy and its correlation with the interval to surgery especially analyzing patients with mesorectal fascia involvement. METHODS: A total of 155 patients with locally advanced rectal cancer treated with preoperative radiotherapy (5×5Gy) were retrospectively analyzed. Tumor response in terms of rates of complete pathological response, downstaging, tumor regression grading and status of the circumferential resection margin were quantified. RESULTS: The mean interval from radiotherapy to surgery was 23 days. The rate of complete pathological response was 2.2% and 28% experienced downstaging (stage decreased). No differences between these rates and interval to surgery were detected. Eighty-eight patients had magnetic resonance imaging for staging (in 31 patients the mesorectal fascia was involved).The mean time to surgery in patients with involvement of the fascia and R0 surgery was 27 days and 16 days if R1 (P=.016). The cutoff of 20 days reached the highest probability of achieving a free circumferential resection margin between patients with mesorectal fascia involvement, with no statistically significant differences: RR 3.036 95% CI=(0.691-13.328), P=.06. CONCLUSIONS: After preoperative short-course radiotherapy, an interval>20 days enhances the likelihood of achieving a free circumferential resection margin in patients with mesorectal fascia involvement.


Subject(s)
Rectal Neoplasms/radiotherapy , Rectal Neoplasms/surgery , Adult , Aged , Aged, 80 and over , Combined Modality Therapy , Fascia/pathology , Female , Humans , Male , Middle Aged , Neoplasm Invasiveness , Preoperative Care , Rectal Neoplasms/pathology , Retrospective Studies , Time Factors , Treatment Outcome
10.
World J Clin Oncol ; 6(4): 30-4, 2015 Aug 10.
Article in English | MEDLINE | ID: mdl-26266098

ABSTRACT

The concept of oligometastatic disease was first described by Hellman and Weichselbaum in 1995. The mere insight of this concept led to the hypothesis that this disease may be cured using local ablative weapons. Surgery has already demonstrated this hypothesis. Surgery limitations, either technical or due to refusal or associated comorbidity, have led to implement alternative ablative options such as stereotactic body radiation therapy (SBRT). SBRT evolved from (stereotactic radiosurgery) because of the need to irradiate extracranial lesions and has been shown to be safe and effective. SBRT achieves local control rates ranging from 70%-90%, but highly variable survival rates depending on the group analyzed. Series with heterogeneous metastatic sites and tumor origin have reported 20% survival rates at 2-3 years, similar to those achieved with surgery. Despite its excellent results, SBRT still faces significant clinical challenges. Its optimal integration with systemic treatment is unknown, and response assessment is very difficult. However, the greatest challenge lies in selection of patients most likely to remain oligometastatic, those who will most benefit from the technique. Biomarkers, molecular signatures, that accurately predict the biological behavior of malignancy are needed. The expression profile of specific miRNAs has been shown to have a potential in this regard.

11.
Brain Tumor Pathol ; 32(2): 124-30, 2015 Apr.
Article in English | MEDLINE | ID: mdl-24984922

ABSTRACT

BACKGROUND: The rosette-forming glioneuronal tumour (RGNT) is a rarely encountered tumour that has been included as a new entity in the 2007 edition of the "World Health Organization (WHO) Classification of Tumours of the Central Nervous System". We describe a rather unusual case of multifocal cerebellar RGNT, located in the spinal cord and displaying leptomeningeal spread. CLINICAL PRESENTATION: Twenty-four-year-old male with history of long-lasting headaches. A magnetic resonance scan revealed three heterogeneous lesions located within both cerebellar hemispheres and the left cerebellopontine angle, in addition to a spinal cord lesion at the level of the cervical region, and images of leptomeningeal spread. Interventions were performed in two stages; these involved resection of two cerebellar lesions, with a histopathological diagnosis of RGNT with atypical microvascular proliferation and focal necrosis. Although these tumours appear to be benign, our case debuted in an aggressive form, both from the radiological point of view and with respect to its histopathological characteristics. For this reason, the patient received adjuvant therapy with chemotherapy and radiotherapy. CONCLUSIONS: Experience of RGNT is limited. The prognostic significance of the histological findings of vascular proliferation and necrosis is still unknown. The clinical improvement in our patient endorses our decision to perform aggressive treatment.


Subject(s)
Cerebral Ventricle Neoplasms/pathology , Fourth Ventricle/pathology , Glioma/pathology , Neuroma/pathology , Spinal Cord Neoplasms/pathology , Spinal Cord/pathology , Adult , Cerebral Ventricle Neoplasms/blood supply , Cerebral Ventricle Neoplasms/therapy , Combined Modality Therapy , Diagnostic Imaging , Disease Progression , Glioma/blood supply , Glioma/therapy , Humans , Male , Microvessels/pathology , Necrosis , Neoplasm Invasiveness , Neuroma/blood supply , Neuroma/therapy , Spinal Cord Neoplasms/blood supply , Spinal Cord Neoplasms/therapy , Treatment Outcome , Young Adult
12.
Clin Transl Oncol ; 13(2): 115-20, 2011 Feb.
Article in English | MEDLINE | ID: mdl-21324800

ABSTRACT

INTRODUCTION: Radiotherapy is a basic weapon in the local treatment of multiple solid tumors. The radiotherapy activity has been evaluated in our centre during the past eleven years. The study focused on rectal cancer. MATERIALS AND METHODS: This is a descriptive study of all radiotherapy procedures performed between January 1998 and December 2008. It quantifies the workload of each pathology treated, the rate of irradiation and its adequacy with optimal rates of irradiation according to the best available scientific evidence. RESULTS: We quantified 9,622 external radiotherapy procedures of which 6,009 were associated with the five pathologies that involved the highest workloads. Of these, 905 were performed in rectal cancer. The workloads due to cancers of the breast, prostate, lung, gynaecological pathologies and rectal cancers were 23.2%, 11.8%, 11.6%, 6.3% and 9.3% respectively. The real "radiotherapy utilisation rates" of these pathologies were 62%, 20.2%, 34.3%, 21% and 64% respectively, while the "rates of adequacy" were 74.7%, 33.6%, 45.1%, 60% and 104.8%. CONCLUSIONS: The "radiotherapy utilisation rate" for rectal cancer was equivalent to the estimated optimum rate as defined on the basis of reference groups. The therapy utilised developed chronologically in parallel with the available scientific evidence. The radiotherapy utilisation rates for breast and prostate cancer gradually increased, with a tendency to reach optimal rates. Radiotherapy as a treatment for lung cancer was underutilised. In global terms, the rate of utilisation of radiation therapy was low, although it displayed a tendency to increase.


Subject(s)
Carcinoma/radiotherapy , Radiotherapy, Adjuvant/adverse effects , Radiotherapy, Adjuvant/methods , Radiotherapy, Adjuvant/statistics & numerical data , Rectal Neoplasms/radiotherapy , Adult , Aged , Aged, 80 and over , Breast Neoplasms/pathology , Breast Neoplasms/radiotherapy , Carcinoma/epidemiology , Carcinoma/pathology , Female , Genital Neoplasms, Female/pathology , Genital Neoplasms, Female/radiotherapy , Humans , Incidence , Lung Neoplasms/pathology , Lung Neoplasms/radiotherapy , Male , Middle Aged , Prostatic Neoplasms/pathology , Prostatic Neoplasms/radiotherapy , Radiation Oncology/methods , Radiation Oncology/trends , Rectal Neoplasms/epidemiology , Rectal Neoplasms/pathology , Retrospective Studies , Workload/statistics & numerical data
SELECTION OF CITATIONS
SEARCH DETAIL
...